Background: Achalasia is a disease of mechanical esophageal dysfunction character-
establish a diagnosis of achalasia and follow treatment outcomes. [2] [3] [4] [5] While these tests are also used to monitor treatment response, a selfreported measure of symptom severity is often the primary outcome in clinical studies and is often the principal factor that drives clinical management decisions. 2, [6] [7] [8] Although other achalasia-symptom scoring tools are used, including the Achalasia severity score, Vantrappen Dysphagia Score, and
Watson dysphagia score, 7-10 the Eckardt symptom score (ESS) is a simple and more commonly used measure to grade symptom severity for achalasia patients in both clinical and research settings.
6,11-13
Nevertheless, a formal validation study to determine if the ESS is an optimal means to gauge achalasia symptoms has not been performed.
In 2009, the US Food and Drug Administration (FDA) guidelines for scale development outlined three steps to produce a measure that is adequately validated for use in clinical trials: initial patient interviews/ focus groups to generate scale items, administering the scale to a large and representative sample of patients, and reviewing the scale items via structured cognitive interviews with an additional small cohort of target patients. 14 As the ESS was developed in 1992, prior to these new FDA guidelines, it has not undergone rigorous validation and reliability testing.
The purpose of this study is to systematically evaluate the factor structure, reliability, and construct validity of the ESS for the grading of achalasia symptoms. Specifically, we aim to (i) Evaluate the factor structure and inter-item correlations of the ESS items via standard statistical practices, (ii) Determine the reliability of the ESS via traditional measures of internal consistency and split-half reliability, and 
| METHODS
This study utilizes a cross-sectional, correlational, non-randomized design. A convenience sample obtained from a university-based outpatient gastroenterology practice is included.
| Patient selection
Patients were identified for retrospective evaluation using a query of 
| Symptom assessment tools
Participants completed the following paper-based questionnaires at the time of HRM.
| Eckardt symptom score 13
The ESS is a 4 item self-report scale measuring weight loss in kilograms, chest pain, regurgitation, and dysphagia. Each item is graded on a score of 0 to 3, with a maximum score of 12. Scores greater than or equal to 3 are considered suggestive of active achalasia. The ESS is widely used in both clinical and research settings as a gold standard for measuring achalasia symptom severity.
| Gastro-esophageal reflux disease questionnaire 15
The GERDQ is a widely used, 6-item self-report measure of reflux symptom severity. Questions evaluate four positive predictors for GERD (heartburn, regurgitation, sleep disruption because of symptoms, and increases in medication use to control GERD), and two
Key Points
• The Eckardt symptom score (ESS) is the gold standard assessment for achalasia and was developed prior to current guidelines for patient reported outcome measure development.
• The ESS demonstrates fair internal consistency and splithalf reliability. Validity is supported by modest relationships with measures of esophageal symptoms and physiological data. Weight loss and chest pain appear to have weak psychometric properties.
• As the ESS is widely used, item refinement may be warranted to ensure the most accurate assessment of patient outcomes.
negative predictors (epigastric pain and nausea). Across studies, the GERDQ demonstrates good reliability and validity. 16 The BEDQ is a 10-item, recently validated self-report measure of esophageal dysphagia that also assesses for food impactions. The frequency and difficulty with swallowing solid foods, soft foods, and liquids are rated on a 5-point Likert scale for 8 items over the past 30 days. An additional 2 items measure how many instances of food impaction lasting more than 30 minutes or requiring an emergency department visit occurred in the past year.
| Brief esophageal dysphagia questionnaire

| NIH PROMIS global health scale 17
The PROMIS Global Health short form is a 10-item instrument representing degradations in multiple domains of health-related quality of life: overall physical health, mental health, social health, pain, fatigue,
and overall perceived quality of life. The scale yields an overall total score and a Global Physical Health (GPH) score and a Global Mental Health (GMH) score. Higher scores denote better HRQOL.
| High resolution manometry
Manometry studies were completed using a 4. the Chicago Classification v3.0, using a median IRP of >15 mmHg as the upper-limit of normal. 19 Although the Chicago Classification was designed and intended for patients without previous surgery, we also utilized the classification scheme during the follow-up (post-treatment) evaluation to objectively describe the motility patterns.
| Timed barium esophagram
Timed barium esophagrams were performed in the upright position with x-ray images of the esophagus obtained at 1, 2, and 5 minutes after ingestion of 200-ml of low-density (45% weight to volume) barium sulfate. The height of the barium column was measured vertically from the EGJ.
| Statistical analyses
All data were imported into SPSS v. 24 for Macintosh (Chicago, IL, USA) for analyses. Preliminary descriptive statistics evaluated the dataset for normality to determine need for non-parametric tests. 
| RESULTS
A total of 107 patients with achalasia were identified via the initial registry query; of these, 83 had only complete post-treatment evaluations (POST) and 24 had complete pre-and post-treatment evaluations (PREPOST). Demographic and clinical characteristics of the study sample by group are outlined in Table 1 .
| Psychometric properties of the Eckardt symptom score
The ESS demonstrated fair internal consistency (Cronbach α = 0.67) and split-half reliability (Guttman statistic = 0.66). From the PCFA, dysphagia accounted for 53% of the variance in symptom score, followed by regurgitation (24%), chest pain (12%) and weight loss (11%).
Inter-item correlations range from small and non-significant to modest, indicating no multicollinearity present in the ESS, but also suggesting that weight loss may be unrelated to the other ESS items (Table 2) .
Convergent and content validity of the ESS is supported by modest
and significant correlations with the GERDQ, HRQOL, and physiological data with the exception of EGJP (Table 3) . Individual ESS item correlations with questionnaire and physiological data are of mixed size and significance, with weight loss the most consistently showing weak or no relationship with other study measures.
| Mean change and effect sizes for Eckardt symptom score following intervention
Follow-up evaluations for the PREPOST group were obtained at a median (interquartile range) 12 (8-14) months after treatment. Evaluation of the ESS between pre-and postsurgical assessment demonstrates significant improvements across the total score and each item, with the exception of weight loss (Table 4) . Effect sizes are moderate to large, with the greatest clinically significant change in regurgitation score, followed by dysphagia, chest pain then weight loss. Changes in physiological, GERDQ, BEDQ, and HRQOL variables are of similar size and range.
| DISCUSSION
While the Eckardt symptom score is a widely used, gold standard measure of achalasia symptom severity, this is the first study to systematically evaluate its reliability and validity in a well-defined patient population. Overall, the ESS demonstrates fair reliability, with measures of internal consistency and split-half reliability falling just under the standard acceptable cutoff score of 0.70. This may simply be a statistical artifact of the short nature of the ESS (4 items). Additionally, there is potential for variability in the ESS based on assessment points. In the present study, the ESS specifies weight loss from symptom onset, if done at baseline, or since surgery if measured at follow-up. However, no timeframe is included in ESS description of the measure. Thus, assessment times could vary substantially between patients. Lastly, obese patients with achalasia may manage to eat in spite of their esophageal dysfunction or patients may opt for high calorie, easy to eat foods such as ice cream which would translate to weight maintenance or even gain. 23 As expected for a short measure, the ESS consists of one uniform scale of which over 50% of the variance is explained by the dysphagia There are limitations to the present study that should be considered when interpreting its results. While achalasia is a rare disease, the present study sample is smaller than desired for psychometric evaluations, especially PCFA and internal consistency. However, the short nature of the ESS likely offsets some of these statistical issues.
Test-retest reliability was not measured in the present study, so we are unable to comment on the ESS's temporal stability.
To improve evaluation of achalasia symptom severity, refinement of the ESS may be necessary. T A B L E 4 Paired samples t-test and effect sizes for ESS, physiological variables, GERDQ, BEDQ, and HRQOL for pre-and postsurgical assessment
